Kurve Therapeutics, Inc.

Kurve Therapeutics drug delivery technology is designed to target the most difficult part of the treatment process - getting medication through the blood-brain barrier and into the brain. Kurve Therapeutics has 18 peer-reviewed publications of clinical trials using their breakthrough technology, with further publications pending. The company has recent and ongoing collaborations with leading research centers including Harvard, Johns Hopkins, and the Karolinska Institute. Through the development of their patented Controlled Particle Dispersion technology, Kurve Therapeutics aims to reshape the landscape of cognitive aging, neurodegenerative diseases, and related disorders. Its next-generation technology has been shown to deliver up to 30x more disease-modifying medication directly to the brain than infusions in several Phase II studies. This allows for significant dose flexibility away from toxic doses for a safer, more efficacious therapy.